Quantum Genesis AI Corp. Issues Statement Regarding OTC Markets Caveat Emptor Designation
MWN-AI** Summary
On March 12, 2026, Quantum Genesis AI Corp. (OTC: QGAI), a company specializing in artificial intelligence and computational modeling, issued an official statement addressing the Caveat Emptor designation issued by OTC Markets Group, Inc. on February 12, 2026. The designation, indicating "buyer beware," arose from a stated "public interest concern," prompting Quantum Genesis AI to seek clarification and engage in dialogue with OTC Markets to resolve the issue.
The Company has made multiple attempts to understand the reasoning behind this designation and any necessary corrective actions. OTC Markets has advised that the review process for the Caveat Emptor status can be formally requested starting March 13, 2026, and Quantum Genesis AI plans to take this opportunity to initiate the review process as soon as possible.
CEO Naveen Kulkarni emphasized the company's commitment to transparency and collaboration with OTC Markets, stating their goal is to clarify the situation and undertake appropriate measures during the review. The Company remains dedicated to keeping shareholders and the investment community informed as new details emerge.
Quantum Genesis AI, known for its focus on advanced technologies at the intersection of AI and scientific innovation, aims to leverage data-driven tools for research and technology development. As they navigate this situation, the Company is committed to upholding robust corporate governance and providing updates to stakeholders.
For more information, investors and interested parties can visit the company's website at www.qgaicorp.com or view its profile on OTC Markets.
MWN-AI** Analysis
Quantum Genesis AI Corp. (OTC: QGAI) is currently facing a Caveat Emptor designation from OTC Markets due to "public interest concerns." This designation acts as a warning to potential investors, highlighting the need for caution when considering investments in the company. In light of these circumstances, it is crucial for investors to approach QGAI stock with a careful mindset.
As of March 12, 2026, the company's management has taken initial steps to address the situation, emphasizing their commitment to transparency and cooperation with OTC Markets. CEO Naveen Kulkarni indicated that the company would request a review of the Caveat Emptor designation starting March 13, 2026. The outcome of this review will likely impact investor sentiment and the stock's future trajectory significantly.
For investors considering entering or holding a position in QGAI, it is imperative to monitor developments closely. Engaging in due diligence by reviewing company communications, financial statements, and industry trends will empower investors to make informed decisions. Given the challenges posed by the designation, prudent investors may wish to adopt a wait-and-see approach until there is clarity on the issue. This strategy could help mitigate risks while keeping the potential for future gains in mind, especially given the company’s focus on artificial intelligence and technology innovation—a sector with promising long-term prospects.
In conclusion, while Quantum Genesis AI has a compelling technological narrative, the current Caveat Emptor designation raises valid concerns. Investors should remain vigilant, await further updates from the company regarding the designation, and consider engaging with financial advisors to tailor their investment strategies accordingly.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SAN DIEGO, CA - March 12, 2026 (NEWMEDIAWIRE) - Quantum Genesis AI Corp. (OTC: QGAI), a technology company focused on artificial intelligence, computational modeling, and scientific innovation, today issued a statement regarding the Caveat Emptor designation placed on the Company’s securities by OTC Markets Group, Inc. on February 12, 2026.
Since the designation was applied, the Company has made several attempts to communicate with OTC Markets in order to better understand the basis for the designation and to determine what steps may be necessary to address the matter. OTC Markets has indicated that the designation relates to a “public interest concern.” The Company has requested additional clarification and intends to continue cooperating with OTC Markets in order to address the matter.
OTC Markets recently informed the Company that it may formally request a review of the Caveat Emptor designation beginning March 13, 2026. Quantum Genesis AI intends to engage with OTC Markets at the earliest available opportunity to initiate that review process.
“We take this matter seriously and are committed to working constructively with OTC Markets to better understand the basis for the designation,” said Naveen Kulkarni, Chief Executive Officer of Quantum Genesis AI Corp. “Our objective is to obtain clarity regarding the matter and to take any appropriate steps necessary as we move through the review process.”
The Company remains committed to maintaining transparency with its shareholders and the broader investment community. Quantum Genesis AI intends to continue cooperating with OTC Markets and will provide updates as additional information becomes available.
For more information and updates, please visit www.qgaicorp.com and the Company’s profile at www.otcmarkets.com/stock/QGAI.
About Quantum Genesis AI Corp.
Quantum Genesis AI Corp. is focused on advancing next-generation technologies at the intersection of artificial intelligence, computational modeling, and scientific innovation. The Company’s strategy includes leveraging advanced data-driven tools to support research, discovery, and technology development across emerging sectors while maintaining a commitment to transparency and responsible corporate governance.
Disclaimer
The information contained in this press release is provided by Quantum Genesis AI Corp. (“Quantum Genesis AI” or the “Company”) for general informational purposes only. This release may include forward-looking statements that reflect the Company’s current expectations, estimates, projections, and assumptions about future events, business performance, market conditions, or technological developments. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. Forward-looking statements are based on management's beliefs and assumptions as of the date of this press release and are subject to change without notice.
Quantum Genesis AI makes no representations or warranties, express or implied, regarding the accuracy, completeness, or reliability of the information contained herein. The Company undertakes no obligation to publicly update or revise any forward-looking statements as a result of new information, future developments, or changes in expectations, except as required by applicable law. Past performance should not be taken as an indicator of future results, and readers should not place undue reliance on any projections or expectations presented in this release.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor does it provide financial, investment, or legal advice. Readers and investors are encouraged to conduct their own due diligence and seek independent professional advice before making any investment or business decisions related to Quantum Genesis AI or its affiliates.
Contact
Naveen Kulkarni
Chief Executive Officer
Quantum Genesis AI Corp.
15656 Bernardo Center Drive, Suite 801
San Diego, CA 92127
Phone: +1 (858) 225-2902
Email: info@qgaicorp.com
Website: www.qgaicorp.com
View the original release on www.newmediawire.com
FAQ**
What specific concerns from the public led to the Caveat Emptor designation for Quantum Genesis AI Corp Com (New) QGAI, and how does the company plan to address them?
As Quantum Genesis AI Corp Com (New) QGAI prepares to request a review of the Caveat Emptor designation, what steps are being taken to ensure a transparent communication process with OTC Markets?
How does Quantum Genesis AI Corp Com (New) QGAI's focus on artificial intelligence and scientific innovation influence its strategic response to the Caveat Emptor designation?
What mechanisms does Quantum Genesis AI Corp Com (New) QGAI have in place to maintain transparency with shareholders amid the uncertainties surrounding the Caveat Emptor designation?
**MWN-AI FAQ is based on asking OpenAI questions about Quantum Genesis AI Corp Com (New) (OTC: QGAI).
NASDAQ: QGAI
QGAI Trading
-33.33% G/L:
$0.20 Last:
1,000 Volume:
$0.30 Open:
